Dapsone tablets

国: アルメニア

言語: 英語

ソース: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ダウンロード 製品の特徴 (SPC)
03-05-2022

有効成分:

dapsone

から入手可能:

Arpimed LLC

ATCコード:

J04BA02

INN(国際名):

dapsone

投薬量:

100mg

医薬品形態:

tablets

パッケージ内のユニット:

(50/5x10/) in blister

処方タイプ:

Prescription

認証ステータス:

Registered

承認日:

2022-05-03

製品の特徴

                                SUMMARY PRODUCT CHARACTERISTIC
DAPSONE
100 MG TABLETS
1.1. TRADE NAME -
Dapsone
1.2. INTERNATIONAL NON-PROPERTY NAME
– Dapsone
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
_ACTIVE INGREDIENT:_
Dapsone – 100 mg;
_For a full list of excipients, see section 6.1. _
_ _
3. PHARMACEUTICAL FORM
White or off-white biconvex, scored tablets with a few small darker
spots.
4. CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
1. As part of a multi-drug regimen in the treatment of all forms of
leprosy.
2. Treatment of dermatitis herpetiformis and other dermatoses.
3. Prophylaxis of malaria in combination with pyrimethamine.
4. Prophylaxis of Pneumocystis carinii pneumonia in immunodeficient
subjects, especially AIDS
patients.
4.2. POSOLOGY AND METHOD OF ADMINISTRATION
_Posology_
_ADULTS AND CHILDREN OVER 12 YEARS:_
_Multibacillary leprosy (3-drug regimen):_
100mg daily for at least two years.
_Paucibacillary leprosy (2-drug regimen):_
100mg daily for at least six months.
_Malaria prophylaxis:_
100mg weekly with 12.5mg pyrimethamine.
_Dermatitis herpetiformis:_
Initially 50mg daily, gradually increased to 300mg daily if required.
Once
lesions have begun to subside, the dose should be reduced to a minimum
as soon as possible, usually
25-50mg daily, which may be continued for a number of years.
Maintenance dosage can often be
reduced in patients receiving a gluten-free diet.
_Pneumocystis carinii pneumonia:_
In combination with trimethoprim, 50-100mg daily; 100mg twice
weekly or 200mg once weekly.
_CHILDREN 6-12 YEARS:_
_Multibacillary leprosy (3-drug regimen):_
50mg daily for at least two years.
_Paucibacillary leprosy (2-drug regimen):_
50mg daily for at least six months.
_ELDERLY:_
Dosage should be reduced in the elderly where there is an impairment
of hepatic function.
_Method of Administration_
For oral administration.
4.3. CONTRAINDICATIONS
Known hypersensitivity to sulfonamides, sulfones, or any of the
excipients; severe anaemia; porphyria;
severe glucose-6-phosphate dehydrogenase deficiency.
4.4. 
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

情報リーフレット 情報リーフレット ロシア語 03-05-2022

この製品に関連するアラートを検索

ドキュメントの履歴を表示する